Literature DB >> 26268712

Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease.

Roslyn J Simms1, Kah Mean Thong2, Gabriel C Dworschak3, Albert C M Ong1.   

Abstract

BACKGROUND: The psychosocial impact of living with autosomal dominant polycystic kidney disease (ADPKD) is poorly understood. In this study, we assessed the overall quality of life (QOL), mood, perceived social support and psychosocial risk of having a diagnosis of ADPKD in a patient cohort from a major UK nephrology centre serving a large catchment population.
METHODS: A postal questionnaire was sent to 349 patients registered at the Sheffield Kidney Institute with chronic kidney disease but not on renal replacement therapy (RRT). The questionnaire incorporated three validated forms: kidney disease quality-of-life short form (KDQOL SF1.3) to assess QOL; nine-item patient health questionnaire (PHQ9) to screen for depression; multidimensional scale of perceived social support (MSPSS) to evaluate perceived social support; as well as a novel genetic psychosocial risk instrument (GPRI-ADPKD) designed to study the specific psychosocial impact of coping with a diagnosis of ADPKD.
RESULTS: The overall response rate was 53%. Patients with a lower estimated glomerular filtration rate (<30 mL/min) or larger kidneys (mean length on ultrasound ≥17 cm) reported reduced QOL and increased psychosocial risk. Clinically significant depression was reported in 22% and 62% felt guilty about passing ADPKD on to their children. In multivariate analysis, female gender was associated with overall poorer psychosocial well-being, whereas increasing age, lower kidney function, larger kidneys and loss of a first degree relative from ADPKD were additional risk factors for QOL, depression or psychosocial risk, respectively.
CONCLUSIONS: Our results reveal a significantly poorer QOL and increasing psychosocial risk with markers of disease progression in patients, particularly women, with ADPKD prior to starting RRT. The future management strategy of ADPKD should address these issues and provide for better individual and family support throughout the patient journey.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  ADPKD; depression; eGFR; psychosocial risk; quality of life; social support

Mesh:

Year:  2015        PMID: 26268712     DOI: 10.1093/ndt/gfv299

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  18 in total

Review 1.  Polycystic kidney disease.

Authors:  Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres
Journal:  Nat Rev Dis Primers       Date:  2018-12-06       Impact factor: 52.329

2.  The relationship between depression, anxiety, quality of life levels, and the chronic kidney disease stage in the autosomal dominant polycystic kidney disease.

Authors:  Aysenur Miray Yarlioglu; Ebru Gok Oguz; Ayse Gokcen Gundogmus; Kadir Gokhan Atilgan; Hatice Sahin; Mehmet Deniz Ayli
Journal:  Int Urol Nephrol       Date:  2022-10-02       Impact factor: 2.266

3.  Demographic and clinical characteristics of children with autosomal dominant polycystic kidney disease: a single center experience

Authors:  Belde Kasap Demir; Fatma Mutlubaş; Eren Soyaltın; Caner Alparslan; Merve Arya; Demet Alaygut; Seçil Arslansoyu Çamlar; Afig Berdeli; Önder Yavaşcan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

Review 4.  Autosomal dominant polycystic kidney disease: recent advances in clinical management.

Authors:  Zhiguo Mao; Jiehan Chong; Albert C M Ong
Journal:  F1000Res       Date:  2016-08-18

Review 5.  Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?

Authors:  Stéphanie De Rechter; Luc Breysem; Djalila Mekahli
Journal:  Front Pediatr       Date:  2017-12-20       Impact factor: 3.418

6.  Is It Ethical to Test Apparently "Healthy" Children for Autosomal Dominant Polycystic Kidney Disease and Risk Medicalizing Thousands?

Authors:  Tess Harris
Journal:  Front Pediatr       Date:  2018-01-19       Impact factor: 3.418

Review 7.  Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.

Authors:  Rashid A Barnawi; Rahaf Z Attar; Sultan S Alfaer; Osama Y Safdar
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-02-01

Review 8.  The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.

Authors:  Myrte K Neijenhuis; Wietske Kievit; Ronald D Perrone; Jeff A Sloan; Patricia Erwin; Mohammad Hassan Murad; Tom J G Gevers; Marie C Hogan; Joost P H Drenth
Journal:  BMC Nephrol       Date:  2017-05-25       Impact factor: 2.388

9.  Health-related quality of life across all stages of autosomal dominant polycystic kidney disease.

Authors:  Daniel Eriksson; Linda Karlsson; Oskar Eklund; Hans Dieperink; Eero Honkanen; Jan Melin; Kristian Selvig; Johan Lundberg
Journal:  Nephrol Dial Transplant       Date:  2017-12-01       Impact factor: 5.992

10.  What are the information needs and concerns of individuals with Polycystic Kidney Disease? Results of an online survey using Facebook and social listening analysis.

Authors:  Tiffany Ma; Kelly Lambert
Journal:  BMC Nephrol       Date:  2021-07-14       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.